Compare · LUCY vs STAA
LUCY vs STAA
Side-by-side comparison of Innovative Eyewear Inc. (LUCY) and STAAR Surgical Company (STAA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LUCY and STAA operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- STAA is the larger of the two at $1.49B, about 256.8x LUCY ($5.8M).
- Over the past year, LUCY is down 67.2% and STAA is up 74.9% - STAA leads by 142.1 points.
- STAA has hit the wire 4 times in the past 4 weeks while LUCY has been quiet.
- STAA has more recent analyst coverage (25 ratings vs 0 for LUCY).
- Company
- Innovative Eyewear Inc.
- STAAR Surgical Company
- Price
- $0.91-5.40%
- $30.02+0.50%
- Market cap
- $5.8M
- $1.49B
- 1M return
- -14.29%
- +8.14%
- 1Y return
- -67.17%
- +74.94%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 0
- 4
- Recent ratings
- 0
- 25
STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Latest LUCY
- Innovative Eyewear Inc. Reports Q1 2026 Unaudited Financial Results
- SEC Form 10-Q filed by Innovative Eyewear Inc.
- Innovative Eyewear, Inc. Announces Real-Time AI Translated Calls for the Lucyd App
- Amendment: SEC Form SCHEDULE 13G/A filed by Innovative Eyewear Inc.
- Innovative Eyewear, Inc. Announces Preliminary Q1 2026 Results
- Innovative Eyewear, Inc. Receives Red Dot Design Award on Lucyd Armor Smart Safety Glasses
- Innovative Eyewear, Inc. Announces New Reebok Optical Collection and Retail Placements
- Innovative Eyewear, Inc. Announces New Smart Safety Glasses and Rx Safety Partner
- Innovative Eyewear Inc. Reports Full Year 2025 Financial Results
- SEC Form 10-K filed by Innovative Eyewear Inc.
Latest STAA
- STAAR Surgical Announces Participation in Upcoming Investor Conferences
- Chief Development Officer Michna Magda was granted 19,795 shares and covered exercise/tax liability with 9,703 shares, increasing direct ownership by 31% to 42,783 units (SEC Form 4)
- Interim Co-CEO and CFO Andrews Deborah J was granted 15,699 shares and covered exercise/tax liability with 5,632 shares (SEC Form 4)
- Interim Co-CEO and Pres. & COO Foust Warren covered exercise/tax liability with 16,785 shares and was granted 32,990 shares, increasing direct ownership by 24% to 83,112 units (SEC Form 4)
- STAAR Surgical upgraded by Wedbush with a new price target
- SEC Form 10-Q filed by STAAR Surgical Company
- STAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- STAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder Letter
- Interim Co-CEO and Pres. & COO Foust Warren covered exercise/tax liability with 3,448 shares, decreasing direct ownership by 5% to 66,917 units (SEC Form 4)
- Chief Development Officer Michna Magda covered exercise/tax liability with 1,680 shares, decreasing direct ownership by 5% to 32,691 units (SEC Form 4)